Press Releases

Date Title and Summary
Toggle Summary Abbott and Isis Announce Hart-Scott-Rodino Clearance of Abbott's Acquisition of Ibis Biosciences, a Subsidiary of Isis
Toggle Summary Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
Toggle Summary Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
Toggle Summary Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
Toggle Summary ADA Conference Presentations Highlight Isis' Metabolic Disease Program Research Activities
Toggle Summary Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS
FDA Prescription Drug User Fee Act goal date set for August 30, 2018 CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious
Toggle Summary Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
Toggle Summary Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen
Toggle Summary Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Toggle Summary Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency
CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for volanesorsen
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.